MedTrace Logo

Explore the Efficacy and Mechanism of Action of Tezepelumab in Eosinophilic Granulomatosis With Polyangiitis

NCT06230354 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 42

Last updated 2026-04-29

No results posted yet for this study

Summary

RACEMATE is a phase 2b, multicentre, randomised, double-blinded, placebo-controlled study designed to explore the efficacy and mechanism of action of tezepelumab in adults with eosinophilic granulomatosis with polyangiitis (EGPA).

Conditions

  • EGPA - Eosinophilic Granulomatosis With Polyangiitis

Interventions

DRUG

Tezepelumab

Tezepelumab subcutaneous injection

DRUG

Placebo

Placebo subcutaneous injection

Sponsors & Collaborators

  • AstraZeneca

    collaborator INDUSTRY

  • Imperial College London

    lead OTHER

Principal Investigators

  • Salman Siddiqui, MBBS · Imperial College London

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-05-15
Primary Completion
2026-09-30
Completion
2026-09-30
FDA Drug
Yes

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06230354 on ClinicalTrials.gov